WORCESTER, Mass.--(BUSINESS WIRE)--RXi Pharmaceuticals Corporation (Nasdaq: RXII), a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), today announced that it has exercised its option to an exclusive worldwide license to novel technologies from Advirna LLC to enable in vivo delivery of RNAi therapeutics. Terms of the agreement were not disclosed.
